# Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

> **NCT03542669** · PHASE1 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Recurrent Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer

## Interventions

- **DRUG:** 6B11-OCIK Injection
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT03542669
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-03
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2022-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03542669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03542669, "Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03542669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*